Avatrombopag Combined With IST as First-line Treatment for SAA
Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
This single-center study aims to evaluate the early efficacy and safety of avatrombopag
combined with immunosuppressive therapy (IST) in the first-line treatment of severe aplastic
anemia (SAA).